Preferred Pharma Recalls Clindamycin Capsules Due to cGMP Deviations
Preferred Pharmaceuticals recalls 300mg Clindamycin capsules due to current Good Manufacturing Practice deviations. Check your lot numbers for details.
Recall notice
cGMP Deviations
Contact the company
What happened, in plain English
Preferred Pharmaceuticals, Inc. is recalling Clindamycin Hydrochloride Capsules, USP, 300mg in 30-count bottles because of current Good Manufacturing Practice (cGMP) deviations. The affected products were manufactured by Glenmark Pharmaceuticals Limited and distributed nationwide in the United States. A total of 1,190 bottles are involved in this Class II recall. Read more at govinfonow.com/recall/32131-preferred-pharma-recalls-clindamycin-capsules-due-to-cgmp-deviations.
Source Summary by GovInfoNow · govinfonow.com/recall/32131-preferred-pharma-recalls-clindamycin-capsules-due-to-cgmp-deviations · Updated October 9, 2026 · FDA enforcement record: FDA #D-0391-2025
Cite this page
“Preferred Pharma Recalls Clindamycin Capsules Due to cGMP Deviations.” GovInfoNow, updated October 9, 2026. https://govinfonow.com/recall/32131-preferred-pharma-recalls-clindamycin-capsules-due-to-cgmp-deviations. Based on FDA recall #D-0391-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0391-2025%22&limit=1).
Why it’s dangerous
The recall is due to cGMP deviations, which means the manufacturing process did not meet federal quality standards. While the specific nature of the deviation is not detailed in the record, such deviations can potentially affect the safety, strength, quality, or purity of the drug.
Who’s affected
Consumers in the United States who purchased Clindamycin Hydrochloride Capsules, USP, 300mg from Preferred Pharmaceuticals or Glenmark Pharmaceuticals Limited between unspecified dates. Patients relying on these specific lots for treatment are at risk of receiving non-compliant medication.
How to tell if you have this one
Check your bottle for NDC 68788-8685-03 and verify if the lot number matches one of the following: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, or L2324L. The expiration date on the recalled bottles is 7/31/2026.
- Brand
Preferred Pharmaceuticals- Category
Drug
What to do — step by step
Check Your Lot Numbers
Compare the lot numbers on your bottle against the recalled list: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, and L2324L.
Contact Your Pharmacist
If you have a recalled bottle, contact your pharmacist or healthcare provider to discuss replacement options or return procedures.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 19 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Preferred Pharmaceuticals recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0391-2025 (April 18, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0391-2025 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 9, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.